Every 8-K that vTv Therapeutics Inc. (VTVT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VTVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTVT filings page.
vTv Therapeutics reported second quarter 2026 results and updates on its type 1 diabetes program. For the three months ended June 30, 2026, the company recorded a net loss attributable to shareholders of $13.1 million, or $(1.05) per basic and diluted share, with R&D expenses of $8.8 million and G&A expenses of $5.2 million. No revenue was recognized in the quarter.
For the six months ended June 30, 2026, vTv reported revenue of $36,839 (in thousands) and net income attributable to vTv of 11,080 (in thousands), compared with no revenue and a net loss in the prior-year period. Cash and cash equivalents were $86,643 (in thousands) as of June 30, 2026, and the company expects its cash to fund operations through the anticipated topline data readout from the Phase 3 CATT1 trial of cadisegliatin. Enrollment in CATT1 is expected to complete in the third quarter of 2026, a Phase 2a Hybrid CATT1 trial is planned to start before year end 2026, and a Key Opinion Leader event on cadisegliatin and type 1 diabetes is planned for the fourth quarter of 2026.
vTv Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026. Stockholders elected seven directors, including Srinivas Akkaraju, Raymond Cheong, Fahed Al Marzooqi, Richard S. Nelson, Anne Phillips, Paul Sekhri, and Daniel K. Spiegelman, each to serve until the 2027 annual meeting or until a successor is elected and qualified.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 2,964,869 votes for, 1,952 against, and 2,869 abstentions. In addition, they cast a nonbinding advisory vote on executive compensation, with 686,535 votes for, 5,291 against, 1,967,329 abstentions, and 310,535 broker non-votes.
vTv Therapeutics Inc. filed an 8-K describing an update to its existing at-the-market stock sales program. The company has filed a prospectus supplement with the SEC to increase the number of Class A common shares offered under this program to the full amount allowed by the ATM agreement.
To support these issuances, vTv is also filing a legal opinion from Dechert LLP on the validity of the Class A common stock issuable under the ATM program. This opinion is attached as Exhibit 5.1 and is being incorporated by reference into the company’s effective shelf registration statement on Form S-3.
vTv Therapeutics Inc. reported a strong turnaround in its first quarter ended March 31, 2026, driven by a major licensing payment. Revenue was $36.8 million, compared with none a year earlier, and net income attributable to shareholders reached $24.1 million versus a prior net loss of $5.1 million.
The company ended the quarter with $98.1 million in cash and cash equivalents and expects this to fund operations through the anticipated topline data readout from its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. An amended license agreement with Newsoara Biopharma added a $20.0 million upfront payment and potential milestones while keeping strategic focus on cadisegliatin.
vTv Therapeutics Inc. furnished an updated investor presentation highlighting its diabetes-focused pipeline. The deck centers on cadisegliatin (TTP399), a hepatoselective glucokinase activator in Phase 3 CATT1 for type 1 diabetes, which has FDA Breakthrough Therapy Designation and aims to be the first oral adjunctive T1D therapy in the U.S. Phase 2 SimpliciT1 data showed a 0.36% HbA1c reduction versus insulin alone and about 50% fewer symptomatic hypoglycemic episodes, with no diabetic ketoacidosis and a generally similar adverse-event profile to placebo. An earlier T2D study showed a 0.9% HbA1c reduction versus metformin. The presentation states cash of $88.9 as of 12/31/2025 plus an additional $20 received on 2/2/2026, which the company says supports operations past the expected CATT1 topline readout. vTv also outlines partnered programs in psoriasis, cancer, and regional T2D markets, and internal assets including an oral GLP-1 agonist (TTP273) and Nrf2/Bach1 modulators targeting oxidative inflammation.
vTv Therapeutics Inc. reported fourth quarter and full year 2025 results and provided a clinical and corporate update. Cash and cash equivalents were $88.9 million as of December 31, 2025, up from $36.7 million a year earlier, mainly from prior private financing.
For 2025, research and development expenses rose to $17.9 million and general and administrative expenses to $14.9 million. Net loss attributable to vTv shareholders was $27.0 million, or $3.20 per basic share.
The company received a $20.0 million upfront payment in February 2026 from an amended global license with Newsoara for PDE4 inhibitor HPP737, with potential future milestones and royalties. vTv expects to complete enrollment in the CATT1 Phase 3 trial of cadisegliatin for type 1 diabetes in the third quarter of 2026 and states that its strengthened balance sheet funds operations well past the anticipated Phase 3 topline readout.
vTv Therapeutics Inc. released an updated investor presentation outlining its diabetes-focused pipeline and financial position. The company highlights cadisegliatin, an oral glucokinase activator in Phase 3 development as a potential first oral adjunctive therapy for type 1 diabetes in the U.S., with topline CATT1 study data targeted for the second half of 2026.
The presentation cites prior Phase 2 data in T1D showing a 0.36% reduction in HbA1c versus insulin alone and a 50% reduction in symptomatic hypoglycemic episodes, with no diabetic ketoacidosis. Cadisegliatin has FDA Breakthrough Therapy Designation. vTv reports $98 million in cash as of September 30, 2025, plus an additional $20 million received on February 2, 2026, which it says provides runway well past the CATT1 topline readout.
The company also describes additional clinical and preclinical programs in immunology, inflammation, metabolism, oncology, obesity, and oxidative inflammation, along with regional partnerships that could generate royalties and shared economics. Management emphasizes its experienced leadership team and positions the broader portfolio as offering potential non-dilutive funding and future revenue streams.
vTv Therapeutics Inc. reported that its subsidiary vTv Therapeutics LLC entered into a Second Amendment to its license agreement with Newsoara Biopharma Co., Ltd. on January 30, 2026. The amendment expands Newsoara’s rights to vTv’s PDE4 inhibitor HPP737 to cover all countries.
In return, Newsoara will pay an upfront fee of $20 million, development milestone payments of up to $50 million, and sales-related milestones of up to $65 million. The agreement also includes royalties in the mid single digits based on sales volumes, creating multiple potential revenue streams tied to HPP737’s progress and commercial performance.
vTv Therapeutics Inc. furnished an 8‑K announcing financial results for the fiscal quarter ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1, detailing its results.
The report states the information, including Exhibit 99.1, is being furnished and not filed under the Exchange Act, which limits applicability of certain liabilities and incorporation by reference unless specifically cited.
vTv Therapeutics Inc. filed a current report describing its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. On September 10, 2025, the company will join a fireside chat scheduled from 2:35 to 3:10 p.m. EST, available as a live audio webcast and on demand.
The company notes that a link to the webcast will be posted on its website. This communication is furnished under Regulation FD and is expressly stated not to be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference into other securities filings.
vTv Therapeutics Inc. reported the sale of Units consisting of (i) one share of common stock and associated warrants or (ii) a pre-funded warrant and associated warrants. Units including a share sold at $15.265 per Unit and Units including a pre-funded warrant sold at $15.255 per Unit. The company issued pre-funded warrants exercisable for $0.01 with no expiration and issued warrants exercisable for $22.71 (for a share) or $22.70 (for a pre-funded warrant). The Warrants expire on the earlier of the fifth anniversary of issuance or 90 days following announcement of positive top-line data from the company’s ongoing CATT1 clinical trial. The filing includes the form of the pre-funded warrant, the form of the warrant, a Securities Purchase Agreement dated August 29, 2025, a Registration Rights Agreement dated August 29, 2025, and is signed by Paul J. Sekhri, President and CEO, dated September 2, 2025.
vTv Therapeutics Inc. filed a current report to note that it issued a press release on August 12, 2025 announcing its financial results for the fiscal quarter ended June 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference for the detailed results.
The company also lists an exhibit for the cover page interactive data file, which is embedded within the Inline XBRL document. The report clarifies that the financial information furnished, including the press release, is not deemed "filed" for liability purposes under the Exchange Act unless specifically incorporated into another filing.